Lebrikizumab and nemolizumab: atopic dermatitis evidence

Lebrikizumab and nemolizumab are biologic medicines with U.S. indications for moderate-to-severe atopic dermatitis in adults and adolescents aged 12 years and older under defined conditions [1][4]. They target different pathways and were tested in different phase 3 programs. Both improved prespecified outcomes compared with placebo, but there is no randomized head-to-head trial showing that one is superior [2][5].

This is an important comparison to get right. Placing percentages from separate trials side by side can look precise while ignoring differences in background topical treatment, eligibility, endpoints, and analysis. The FDA labels and within-trial comparisons are more reliable than a cross-trial ranking.

How do the targets differ?

Lebrikizumab is an antibody directed at interleukin-13, a cytokine involved in type 2 inflammation and skin-barrier dysfunction. Its FDA label covers patients aged 12 years and older who weigh at least 40 kg and whose moderate-to-severe atopic dermatitis is not adequately controlled with topical prescription therapy, or when those therapies are not advisable [1]. It can be used with or without topical corticosteroids.

Nemolizumab targets interleukin-31 receptor alpha. IL-31 signaling is closely linked to itch as well as inflammation. The U.S. atopic dermatitis label covers adults and adolescents aged 12 years and older whose disease is not adequately controlled with topical prescription therapies [4]. It is labeled in combination with topical corticosteroids and/or topical calcineurin inhibitors.

The labels therefore are not interchangeable:

This table describes regulatory language, not a prescribing recommendation.

What did the lebrikizumab trials test?

ADvocate1 and ADvocate2 were replicate, randomized, double-blind phase 3 trials. Adults and adolescents with moderate-to-severe atopic dermatitis received lebrikizumab monotherapy or placebo during a 16-week induction period [2]. The programs were funded by Dermira, a Lilly company, and several authors were company employees or disclosed industry relationships.

Both studies favored lebrikizumab on the primary Investigator's Global Assessment endpoint—clear or almost clear with at least a two-point improvement from baseline—and on at least 75% improvement in Eczema Area and Severity Index [2]. Response percentages differed between the replicate studies, so no single result is presented here as a benchmark against the separate nemolizumab program.

Responders at week 16 entered randomized maintenance groups. Fifty-two-week findings support maintenance with less frequent administration in some initial responders [3]. That second-stage result applies to people who had already responded and were re-randomized. It should not be presented as the expected outcome for everyone who starts treatment.

What did the nemolizumab trials test?

ARCADIA 1 and ARCADIA 2 were randomized, double-blind phase 3 trials in adults and adolescents with moderate-to-severe atopic dermatitis. Unlike the lebrikizumab monotherapy induction trials, nemolizumab was studied with background topical corticosteroids, with or without topical calcineurin inhibitors [5]. The studies were funded by Galderma, and company employees were among the authors.

Nemolizumab plus background topical therapy outperformed placebo plus background topical therapy on the co-primary outcomes at week 16 [5]. The outcomes assessed clear or almost-clear skin and at least 75% Eczema Area and Severity Index improvement. Itch and sleep outcomes were also measured.

The design difference is central. A nemolizumab response percentage includes the effect of the study's permitted background topical regimen. It cannot be directly ranked against a lebrikizumab monotherapy percentage without a head-to-head design.

An open-label extension reported outcomes through 104 weeks for participants with and without previous nemolizumab exposure [6]. Of 1,901 participants enrolled, 1,062 completed week 104; the analysis used observed data and did not retain a placebo comparison. Most treatment-emergent events were mild or moderate [6]. Longer exposure is valuable for safety surveillance, but an open extension is vulnerable to attrition and responder-selection effects.

Safety profiles are related to the target and label

The lebrikizumab label includes warnings for hypersensitivity, conjunctivitis and keratitis, parasitic infections, and vaccination considerations [1]. In the phase 3 program, conjunctivitis was more common with lebrikizumab than placebo [2]. The correct response is not to assume every eye symptom is drug related or harmless; new eye pain, light sensitivity, or vision change needs clinical assessment.

The nemolizumab label addresses hypersensitivity and vaccination, and its trial program reported events including headache, asthma, and injection-related reactions [4][5][6]. Label wording and rates should not be borrowed from a different biologic simply because both treat atopic dermatitis, and efficacy findings should not be transferred across drug classes or conditions.

Neither medicine is a general treatment for a rash that has not been diagnosed. Contact dermatitis, scabies, fungal infection, cutaneous T-cell lymphoma, drug eruptions, and other conditions can resemble eczema in some settings. A poor response should prompt reassessment rather than automatic escalation.

Why a cross-trial ranking is unreliable

A fair comparison would randomly assign similar participants to one biologic or the other under the same background-treatment and outcome rules. The available pivotal programs did not do that [2][5]. Cross-trial differences include:

• monotherapy induction for lebrikizumab versus required background topical therapy for nemolizumab;
• different randomization and maintenance structures;
• different placebo response rates;
• different handling of rescue treatment and missing data;
• separate sponsor-run programs;
• no shared trial designed to test non-inferiority or superiority.

Mechanism can guide a hypothesis, such as considering prominent itch, but it is not a substitute for comparative clinical evidence. Insurance access, comorbid disease, eye history, injection schedule, prior therapy, and patient priorities can also shape a decision.

Bottom line

Lebrikizumab and nemolizumab both have FDA indications and positive phase 3 evidence for defined patients with moderate-to-severe atopic dermatitis [1][2][4][5]. Lebrikizumab targets IL-13. Nemolizumab targets IL-31 receptor alpha and was tested with background topical therapy.

The evidence supports each medicine against its own control group. It does not support declaring a winner across separate trials. The most accurate comparison keeps the label, trial design, safety profile, and uncertainty attached to each result.

This article is for informational purposes and does not constitute medical advice. Moderate-to-severe atopic dermatitis should be managed with a qualified clinician.